Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience

被引：0
|
作者：
Pizzutilo, P. [1 ]
Catino, A. [1 ]
Montrone, M. [1 ]
Longo, V. [1 ]
Ricci, D. [1 ]
Pesola, F. [1 ]
Marech, I. [1 ]
Mastrandrea, A. [1 ]
Petrillo, P. [1 ]
Zacheo, A. [1 ]
Varesano, N. [1 ]
Lamorgese, V. [1 ]
Bafunno, D. [1 ]
Galetta, D. [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol, Thorac Oncol Unit, Bari, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immune checkpoint inhibitors; Gender-related outcome; advanced lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.14
引用
收藏
页码：S579 / S580
页数：2
相关论文
共 50 条
  • [41] Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors
    Sen, Gulin Alkan
    Oztas, Nihan Senturk
    Degerli, Ezgi
    Guliyev, Murad
    Can, Guenay
    Turna, Hande
    Ozguroglu, Mustafa
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12) : 3264 - 3271
  • [42] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [43] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [44] Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database
    Almutairi, Abdulaati R.
    Slack, Marion
    Erstad, Brian L.
    McBride, Ali
    Abraham, Ivo
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2021, 12
  • [45] Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
    Barghout, Samir H.
    Zhan, Luna Jia
    Raptis, Starvroula
    Al-Agha, Faisal
    Esfahanian, Niki
    Popovacki, Aimee
    Kasymjanova, Goulnar
    Proulx-Rocray, Francis
    Chan, Sze Wah Samuel
    Richardson, Matthew
    Brown, M. Catherine
    Patel, Devalben
    Dean, Michelle Liane
    Navani, Vishal
    Moore, Erica
    Carvery, Lane
    Yan, Elizabeth
    Goldshtein, Daniel
    Cleary-Gosine, Jasmine
    Gibson, Amanda J. W.
    Hubley, Lynn
    Balaratnam, Karmugi
    Ngo, Tran
    Gill, Azee
    Black, Morgan
    Sacher, Adrian
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Cheema, Parneet
    Kuruvilla, Sara
    Agulnik, Jason
    Banerji, Shantanu
    Juergens, Rosalyn
    Blais, Normand
    Cheung, Winson
    Wheatley-Price, Paul
    Liu, Geoffrey
    Snow, Stephanie
    LUNG CANCER, 2024, 194
  • [46] Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies
    Kazuyuki Mizuno
    Takanori Ito
    Masatoshi Ishigami
    Yoji Ishizu
    Teiji Kuzuya
    Takashi Honda
    Hiroki Kawashima
    Yosuke Inukai
    Hidenori Toyoda
    Kenji Yokota
    Tetsunari Hase
    Osamu Maeda
    Hitoshi Kiyoi
    Masato Nagino
    Hideharu Hibi
    Yasuhiro Kodera
    Yasushi Fujimoto
    Michihiko Sone
    Momokazu Gotoh
    Yuichi Ando
    Masashi Akiyama
    Yoshinori Hasegawa
    Mitsuhiro Fujishiro
    Journal of Gastroenterology, 2020, 55 : 653 - 661
  • [47] Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
    Peng, Ziting
    Dong, Jianhui
    Tang, Shuyao
    Shi, Jiaxu
    Shi, Tongdong
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [48] Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies
    Mizuno, Kazuyuki
    Ito, Takanori
    Ishigami, Masatoshi
    Ishizu, Yoji
    Kuzuya, Teiji
    Honda, Takashi
    Kawashima, Hiroki
    Inukai, Yosuke
    Toyoda, Hidenori
    Yokota, Kenji
    Hase, Tetsunari
    Maeda, Osamu
    Kiyoi, Hitoshi
    Nagino, Masato
    Hibi, Hideharu
    Kodera, Yasuhiro
    Fujimoto, Yasushi
    Sone, Michihiko
    Gotoh, Momokazu
    Ando, Yuichi
    Akiyama, Masashi
    Hasegawa, Yoshinori
    Fujishiro, Mitsuhiro
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 653 - 661
  • [49] Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
    Huang, Y.
    Zhao, J. J.
    Soon, Y. Y.
    Kee, A.
    Tay, S. H.
    Aminkeng, F.
    Ang, Y.
    Wong, A.
    Goh, B. C.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S391 - S391
  • [50] Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
    Yang, Yang
    Tan, Lijie
    Hu, Jian
    Li, Yin
    Mao, Yousheng
    Tian, Ziqiang
    Zhang, Baihua
    Ma, Jianqun
    Li, Hecheng
    Chen, Chun
    Chen, Keneng
    Han, Yongtao
    Chen, Longqi
    Liu, Junfeng
    Yu, Bentong
    Yu, Zhentao
    Li, Zhigang
    DISEASES OF THE ESOPHAGUS, 2022, 35 (11)
12345